Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213880 | 0.80 | SLC6A2 (0.43) | DYRK1ASLC6A2HTTKDM4EL3MBTL1 | |
| SCHEMBL21140258 | 0.79 | SLC6A2 (0.40) | DYRK1ASLC6A2HTTKDM4EL3MBTL1 | |
| SCHEMBL11922110 | 0.79 | DYRK1A (0.47) | DYRK1ACCNT1PIM1CCNA2CDK2 | |
| SCHEMBL14197833 | 0.78 | DYRK1A (0.49) | DYRK1ACCNT1PIM1CCNA2CDK2 | |
| SCHEMBL20674508 | 0.78 | HTT (0.46) | SLC6A2HTTKDM4EL3MBTL1NPC1 | |
| SCHEMBL20674192 | 0.78 | DYRK1A (0.49) | DYRK1ACCNT1PIM1CCNA2CDK2 | |
| SCHEMBL22149167 | 0.78 | DYRK1A (0.49) | DYRK1ACCNT1PIM1CCNA2CDK2 | |
| SCHEMBL15792325 | 0.78 | DYRK1A (0.49) | DYRK1ACCNT1PIM1CCNA2CDK2 | |
| SCHEMBL30503547 | 0.78 | DYRK1A (0.49) | DYRK1ACCNT1PIM1CCNA2CDK2 | |
| SCHEMBL16307577 | 0.78 | DYRK1A (0.49) | DYRK1ACCNT1PIM1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022221642-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| WO-2022063197-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | 上海美悦生物科技发展有限公司 | 2022-03-31 | — | — | WO | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020119739-A1 | 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREFOR | 暨南大学 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | DYRK1A 2246/4885CCNT1 623/4885PIM1 3166/4885 |
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | DYRK1A 3264/4885CCNT1 3392/4885PIM1 1191/4885 |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | NR0B1, UGT1A10, NR0B2 | DYRK1A 3150/4885CCNT1 407/4885PIM1 4178/4885 |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, HRH2, PTGDR2 | DYRK1A 797/4885CCNT1 507/4885PIM1 4391/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | DYRK1A 3616/4885CCNT1 3977/4885PIM1 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.